ARTIMPLANT appoints new CEO (press release)
Kjell Thörnbring has been appointed to the new CEO of Artimplant AB. He has been acting CEO since May 4 and he has at the same time maintained the position of CFO. Kjell Thörnbring has a B.Sc in Business Administration from the Gothenburg University and he has previously had leading positions as CEO and CFO in public Swedish companies.
The following changes have also been implemented in Artimplant´s management group:
Susan Linke has been appointed to Financial Manager. She has been employed by the company since 2007. Susan has earlier been an accountant in the company and she has previously a background as Financial Manager.
Hanna Stenhamre has been appointed to manage the new department Clinical Affairs. Hanna has been employed by Artimplant since 2005 and she has been responsible for preclinical research. Hanna holds a MSc from Chalmers University of Technology and she also holds a PhD in biomaterial science from the Gothenburg University. The department of Clinical Affairs is responsible for clinical studies and clinical documentation and it will have a close cooperation with the marketing and sales department.
”Artimplant has during a long period of time had profitability problems and we has had difficulties to achieve set objectives. In connection with the annual shareholder´s meeting a new Board of Directors was elected and a new CEO has now been appointed. In a close cooperation the Board of Directors and the Management revise the company’s activities in order to identify any problems and to take necessary measures in order to create a competitive and profitable company,” says the Chairman of Artimplant Anders Cedronius.